Treating hyperglycemia improves skeletal muscle protein metabolism in cancer patients after major surgery by G. Biolo et al.
Treating hyperglycemia improves skeletal muscle protein
metabolism in cancer patients after major surgery
Gianni Biolo, MD, PhD; Marcello De Cicco, MD; Stefania Lorenzon, MD; Viviana Dal Mas, MD; Dario Fantin,
MD; Rita Paroni, MD; Rocco Barazzoni, MD; Michela Zanetti, MD; Gaetano Iapichino, MD; Gianfranco
Guarnieri, MD
Skeletal muscle plays a pivotalrole in metabolic adaptation tosevere stress. Muscle resis-tance to insulin’s ability to pro-
mote glucose uptake and metabolism di-
rectly contributes to increasing blood
glucose in patients affected by critical ill-
ness or recovering from major surgery
(1). Hyperglycemia has direct negative
effects on endothelial and immune func-
tions (2). Activation of muscle proteolysis
with relative inhibition of protein synthe-
sis leads to muscle wasting and efflux of
free amino acids (3). Glutamine has the
fastest releasing rate because it is largely
synthesized de novo and stored in muscle
cytoplasm. In critical illness and after
major surgery, the muscle glutamine
pool is rapidly depleted to provide free
glutamine both to the liver and rapidly
dividing cells of gut mucosa and the im-
mune system (4). Such increased utiliza-
tion is not matched by sufficient muscle
production (5–7). In addition to amino
acids, asymmetrical (ADMA) and sym-
metrical (SDMA) dimethylarginines, pro-
duced by methylation of arginine resi-
dues in proteins, are also released from
skeletal muscle as obligatory products of
protein turnover (8). ADMA is an endog-
enous inhibitor of nitric oxide synthase
that may cause endothelial dysfunction
(8). In the clinical setting, hyperglyce-
mia, glutamine depletion, and increased
ADMA concentrations were associated
with poor outcome in critically ill pa-
tients (4, 9, 10). Insulin-mediated strict
glucose control and glutamine supple-
mentation decreased morbidity and mor-
tality in selected patients (4, 9).
The present study was designed to ex-
plore potential interactions between
pathways of glucose and amino acid me-
tabolism in skeletal muscle of intensive
care patients. In skeletal muscle, glucose
serves as a precursor for the carbon skel-
eton of glutamine (11). Under physiologic
conditions, glutamine release from skel-
etal muscle increases during euglycemic
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Objective: Cancer and surgical stress interact to aggravate
insulin resistance, protein catabolism, and glutamine depletion in
skeletal muscle. We compared the effects of insulin-mediated
euglycemia and moderate hyperglycemia on kinetics of protein
and selected amino acids in skeletal muscle of female cancer
patients after major surgery.
Design: In each patient, a 24-hr period of insulin-mediated
tight euglycemia (mean blood glucose, 5.8  0.4 mmol/L) pre-
ceded or followed a 24-hr control period of moderate hypergly-
cemia (mean blood glucose, 9.6  0.6 mmol/L) on the first and
second day after surgery, in randomized order, according to a
crossover experimental design.
Setting: Intensive care unit, cancer hospital.
Patients: Cancer patients after abdominal radical surgery com-
bined with intraoperative radiation therapy.
Interventions: Intensive (57  11 units/24 hrs) and conven-
tional (25  5 units/24 hrs) insulin treatment during total paren-
teral nutrition.
Measurements and Main Results: Muscle metabolism was
assessed at the end of each 24-hr period of euglycemia and of
hyperglycemia by leg arteriovenous catheterization with stable
isotopic tracers. We found that euglycemia as compared with
hyperglycemia was associated with higher (p < .05) fractional
glucose uptake (16%  4% vs. 9%  3%); higher (p < .05)
muscle protein synthesis and neutral net protein balance (3 
3 vs.11 3 nmol phenylalanine·100 mL1·min1, respectively);
lower (52%  12%, p < .01) muscle nonprotein leucine dis-
posal (an index of leucine oxidation) and higher (p < .05) plasma
leucine concentrations; and higher (3.6  1.7 times, p < .01) net
de novo muscle glutamine synthesis and plasma glutamine con-
centrations (p < .05). Euglycemia was associated with higher
(23%  7%, p < .05) plasma concentrations of arginine but did
not affect either arginine release from muscle or plasma concen-
tration and muscle flux of asymmetrical dimethylarginine. Rate of
muscle proteolysis correlated (p < .05) with muscle release of
asymmetrical dimethylarginine.
Conclusions: Treating hyperglycemia improves skeletal muscle
protein and amino acid metabolism in cancer patients after major
surgery. (Crit Care Med 2008; 36:1768–1775)
KEY WORDS: insulin; cancer; surgery; skeletal muscle; glycemic
control; glutamine; arginine
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hyperinsulinemia (12, 13) because of in-
creased conversion of glucose to glu-
tamine. A recent study has determined
the effect of hyperglycemia on carbon
transfer rate from glucose to glutamine
during intravenous dextrose infusion in
healthy volunteers and insulin-deprived
type 1 diabetic subjects (11). Hyperglyce-
mia in healthy subjects stimulated car-
bon flux from glucose to glutamine,
whereas the rise in carbon transfer from
glucose to glutamine was not observed in
diabetic subjects. These results suggest
that carbon transfer from glucose to glu-
tamine may depend on adequate insulin
availability and action. Hyperglycemia
can also increase ADMA levels by inhibit-
ing methylarginine intracellular enzy-
matic degradation by the enzyme dim-
ethylarginine dimethylaminohydrolase
(8). Finally, insulin and glucose availabil-
ity have deep influence on the synthesis
and degradation pathways of muscle pro-
tein and on oxidation of individual amino
acids, especially branched chain (14, 15).
We have selected a population of
slightly overweight patients with cancer
who underwent abdominal radical sur-
gery combined with intraoperative radia-
tion therapy (16, 17) to maximize muscle
metabolic alterations (4, 18–20), such as
insulin resistance, acceleration of prote-
olysis, inhibition of protein synthesis, and
glutamine depletion. A 2-day crossover
experimental design was used to compare
the effects of moderate hyperglycemia
and euglycemia, resulting from 24 hrs of
traditional or intensive insulin treatment,
on the rates of skeletal muscle protein syn-
thesis and degradation, leucine oxidation,
glutamine de novo synthesis, and dimethy-
larginine production, as determined by the
leg arteriovenous catheterization and stable
isotopic tracers (21, 22).
METHODS
Patients. We have studied eight adult fe-
male patients (age, 54  4 yrs; body mass
index, 26  2 kg/m2) with colorectal (n  3),
cervical (n  1), endometrial (n  1), ovarian
(n  2), and kidney (n  1) cancer and no
major organ-system diseases, after the com-
plete surgical removal of the tumor in combi-
nation with intraoperative radiation therapy
(16, 17). Informed consent was obtained from
patients before surgery. The experimental pro-
tocol was approved by the ethical committee
of the Centro di Riferimento Oncologico
(CRO), Istituto Nazionale Tumori, IRCCS, Avi-
ano, Italy. After surgery, patients were admit-
ted to the intensive care unit of the Centro di
Riferimento Oncologico of Aviano, Italy. A
continuous intravenous infusion of glucose
(20% solution at 20 mL·kg1·day1), lipids
(Intralipid 10% [Fresenius Kabi AB] at 8
mL·kg1·day1), and mixed amino acids
(Freamine III 8.5% [B. Braun Medical] at 14.4
mL·kg1·day1) was initiated and continued
for the following 48 hrs. Total energy admin-
istration was 28 kcal·kg1·day1.
Experimental Design. Each patient was
studied twice. Two leg muscle metabolic stud-
ies (which included determination of whole
body and muscle protein and amino acid me-
tabolism) were performed at the end of the
24-hr periods of conventional or tight glyce-
mic control. To account for time-related
changes of muscle metabolism after surgery
and for potential interference between two
close stable-isotope infusions, the conven-
tional glycemic control period either preceded
(protocol 1) or followed (protocol 2) the tight
glycemic control period. Patients were ran-
domly assigned to protocol 1 (n  4) or to
protocol 2 (n  4). In the patients assigned to
protocol 1, a conventional insulin treatment
was started after surgery at about 11 am and
continued for 24 hrs (i.e., a continuous infu-
sion of regular insulin was started only if the
blood glucose level exceeded 9.4 mmol/L, and
the infusion was adjusted to maintain the glu-
cose level at a value between 8.3 and 11.1
mmol/L). In the patients assigned to protocol
2, an intensive insulin treatment was started
after surgery at about 11 am and continued for
24 hrs (i.e., an insulin infusion was started if
the blood glucose level exceeded 6.1 mmol/L,
and the infusion was adjusted to maintain
normoglycemia [4.4 to 6.9 mmol/L]) (9). The
next day, a leg muscle metabolic study was
performed in all patients from 8 to 11 am.
Thereafter, in the four patients who previously
received conventional insulin treatment, an
intensive insulin treatment was started and
was continued for 24 hrs. In the other four
patients who previously received intensive in-
sulin treatment, a 24-hr conventional insulin
treatment was commenced. The second met-
abolic study was performed from 8 to 11 am
during the last 3 hrs of either conventional or
intensive insulin treatment. During the two
study days, blood glucose concentrations were
determined approximately every 2 hrs.
Leg Metabolic Study. On the morning of
the first day after surgery, the first leg muscle
metabolic study was performed from 8 am to
11 am. Indwelling catheters placed for clinical
purposes in a femoral and internal jugular
vein and in a radial artery were used for iso-
tope infusion and blood sampling. At 8 am,
femoral venous blood samples were obtained
to measure background phenylalanine enrich-
ment. Then, primed, continuous infusions of
L-[ring-2H5]phenylalanine (Cambridge Iso-
tope Laboratories) were started and main-
tained constant for 3 hrs (prime dose, 1 mol/
kg; infusion rate, 0.02 mol·kg1·min1).
After 160 mins, three blood samples were
taken every 10 mins from the radial artery and
the femoral vein to determine plasma glucose
and amino acid concentrations and phenylal-
anine enrichments. Leg blood flow was mea-
sured by plethysmography after every blood
sample (22). Leg plasma flow was calculated
from the hematocrit. Infusion of labeled phe-
nylalanine was stopped at time 180 mins. On
the morning of the second day after surgery,
the second leg muscle metabolic study was
performed from 8 am to 11 am, as described.
Analysis. Concentrations of selected amino
acids (phenylalanine, leucine, and glutamine)
and isotopic enrichment of L-[ring-
2H5]phenylalanine were measured in plasma
samples taken from the radial artery and fem-
oral vein, as previously described (21, 22). The
stable isotopes L-[1-13C]phenylalanine, L-[1-
13C]leucine, and L-[5-15N]glutamine were
added to the tubes as internal standards (22).
To determine the enrichment of the infused
tracer and the internal standards of free phe-
nylalanine, leucine, and glutamine in the
plasma, the t-butyldimethylsilyl derivatives
were prepared as described by Biolo et al (21).
Tracer/tracee ratios were measured by gas
chromatography–mass spectrometry analysis
(Hewlett-Packard 5985) (21). Plasma concen-
trations of arginine, ADMA, and SDMA were
determined by high-pressure liquid chroma-
tography, as previously described (23). Insu-
lin, C-peptide, and glucose concentrations
were determined by standard methods.
Calculations. Calculations of glucose and
amino acid kinetics used averaged values of
plasma concentrations and enrichments ob-
tained at the end of each leg metabolic study.
Skeletal muscle is considered to largely ac-
count for glucose and amino acid metabolism
in the whole leg (21). The leg muscle net
balance for glucose and amino acids was cal-
culated from the Fick principle:
Net balance  (CA  CV)  F [1]
where CA and CV are plasma glucose or amino
acid concentrations in radial artery and femo-
ral vein, respectively, and F is leg plasma flow.
Positive values indicate net uptake, whereas
negative values indicate net release. In steady-
state condition of amino acid concentrations,
amino acid uptake or release across the leg
reflects the balance between intracellular pro-
duction and disposal for that particular amino
acid. Thus, net phenylalanine release from leg
muscle is a marker of net protein catabolism
(i.e., the difference between protein synthesis
and degradation) because this amino acid is
not synthesized or oxidized in muscle tissue
(21, 22, 24). In contrast, skeletal muscle is the
main site of oxidation of the branched-chain
amino acids leucine, valine, and isoleucine
and of glutamine synthesis from glutamate.
We assumed that amino acids are released
from protein catabolism in proportion to their
relative content in muscle proteins (21). Thus,
the net rates of release from protein catabo-
lism of leucine and glutamine can be calcu-
lated from the net rate of phenylalanine re-
lease corrected for the molar ratios glutamine/
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phenylalanine (i.e., 0.92) and leucine/
phenylalanine (i.e., 3.10) determined in mixed
human muscle protein (21). The rate of net
glutamine de novo synthesis (i.e., the differences
between the rates of de novo synthesis and non-
protein utilization of the amino acid) and of
nonprotein leucine disposal (i.e., and index of
leucine oxidation) can be calculated by subtract-
ing the component accounted for by protein
catabolism from the total release or uptake of
these amino acids (glutamine de novo synthesis
was transformed into a positive number):
Glutamine de novo synthesis
 [net glutamine balance
 (net phenylalanine balance  0.92)] [2]
Nonprotein leucine disposal
 [net leucine balance
 (net phenylalanine balance
 3.10)] [3]
whole body phenylalanine rate of appearance
(Ra) from proteolysis and exogenous infusion
was calculated by standard methodology (i.e., by
dividing L-[ring-2H5]phenylalanine infusion rate
by arterial L-[ring-2H5]phenylalanine tracer/
tracee ratio). Phenylalanine Ra from whole body
proteolysis was calculated by subtracting the in-
fusion rate of exogenous unlabeled phenylala-
nine (i.e., 0.3 mol·kg1·min1) from total
whole body phenylalanine rate of appearance.
Muscle phenylalanine Ra from proteolysis
was calculated as follows (21, 22, 24):
Phenylalanine Ra from proteolysis
 [(CA(PHE)  EA(PHE)  BF)/E V(PHE)]
 (CA(PHE)  F) [4]
C and E indicate values of arterial (A) or fem-
oral venous (V) phenylalanine (PHE) concen-
trations and enrichments, respectively.
Leg muscle phenylalanine rate of disap-
pearance (Rd) to muscle protein synthesis was
calculated as follows (21, 22, 24):
Phenylalanine Rd to protein synthesis
 Phenylalanine Ra from proteolysis
 Net phenylalanine balance [5]
Insulin sensitivity was determined according
to the quantitative insulin-sensitivity check
index (QUICKI) that is determined by a math-
ematical transformation of plasma glucose
and insulin levels as follows (25):
QUICKI  1/[log(I)  log(G)] [6]
where I is plasma insulin concentration (mi-
crounits/mL) and G is plasma glucose concen-
tration (mg/dL). QUICKI is a dimensionless
index without units. During each study day,
values of blood glucose concentrations, deter-
mined approximately every 2 hrs, were plotted
on a graph. The area under the curve was
calculated geometrically from 12 values of
blood glucose concentrations as referenced
(26). Units for area under the curve are blood
glucose concentrations (mmol·L1)  24 hrs.
Data Presentation and Statistics. Each pa-
tient was studied twice. Two leg muscle met-
abolic studies (which included determination
of whole body and muscle protein and amino
acid metabolism) were performed at the end of
24-hr periods of conventional (control) or
tight glycemic control (euglycemia). To ac-
count for time-related changes of muscle me-
tabolism after surgery and for potential inter-
ference between two close stable-isotope
infusions, patients were randomly assigned to
protocol 1 (n  4) or to protocol 2 (n  4). In
protocol 1, the euglycemic period preceded
the hyperglycemic control period. In protocol
2, the euglycemic period followed the hyper-
glycemic control period. Results obtained in
the euglycemic and control periods in subjects
assigned to protocols 1 and 2 were analyzed
with repeated-measures analysis of variance
with intervention (euglycemia/control) and
time (day 1/day 2 after surgery) as the two
factors. Post hoc analysis was performed,
when appropriate, by Student’s t-test with
Bonferroni’s adjustment. There were not sig-
nificant time effects or significant interven-
tion  time interaction for any clinical, bio-
chemical, or kinetic data. Thus, results
obtained during the euglycemic periods on
day 1 or day 2 after surgery were pooled to-
gether and compared with the pooled results
obtained during the hyperglycemic control pe-
riods on day 1 or day 2 after surgery. Results in
the two different experimental conditions
(control and euglycemia) were compared us-
ing the Wilcoxon’s matched-pairs signed-
ranks test. Values of substrate balance across
leg muscle were tested against zero by the
Wilcoxon’s matched-pairs signed-ranks test to
detect significant net release or uptake. Values
of p .05 were taken as significantly different.
Data are presented in Tables 1–3 as mean 
SEM. Individual kinetic results and median val-
ues are shown in Figures 1–3.
RESULTS
Clinical Data and Glucose Kinetics.
Table 1 shows selected clinical data dur-
ing the two study days. Patients were
hemodynamically stable, as shown by the
values of systolic and diastolic arterial
pressure, heart rate, leg plasma flow, and
hematocrit determined during the two
metabolic studies performed on days 1
and 2 after surgery, either in euglycemia
or hyperglycemia (control period).
Plasma creatinine and albumin concen-
trations did not change on days 1 and 2
after surgery either in euglycemia or hy-
perglycemia (control period). There were
not significant time or intervention ef-
fects or time  intervention interaction
Table 1. Clinical data during the experimental period
Protocol 1 Protocol 2 p
Day 1
Euglycemia
Day 2
Control
Day 1
Control
Day 2
Euglycemia
Time
Effect
Intervention
Effect Interaction
SAP (mm Hg) 133  11 132  9 136  5 131  4 .91 .42 .19
DAP (mm Hg) 74  7 75  5 75  3 74  4 .99 .80 .96
Heart rate (beats/min) 79 5 80  3 85  4 86  3 .28 .88 .47
Leg plasma flow (mLmin1100 mL1) 2.45  0.72 1.69  0.38 1.68  0.52 1.37  0.16 .37 .60 .29
Hematocrit (percent) 30.5 1.4 30.5  1.3 30.2  1.6 30.6  1.8 .96 .54 .54
Plasma creatinine (mg/dL) 0.92 0.05 0.89  0.01 0.81  0.06 0.82  0.05 .21 .45 .56
Plasma albumin (g/L) 3.2 0.1 3.2  0.1 3.5  0.1 3.5  0.2 .17 .71 .71
Insulin infusion rate (U24 hrs1) 49  18a 20  8 19  9 43  20a .82 .006 .72
AUC glucose 137  15a 190  12 225  10 147  7a .12 .001 .28
SAP, systolic arterial pressure; DAP, diastolic arterial pressure; AUC, area under the curve of blood glucose concentrations. Units for AUC are blood
glucose concentrations (mmolL1)  24 hrs. Data are expressed as mean  SEM. Data were analyzed with repeated measures analysis of variance with
intervention (euglycemia/control) and time (day one/day two after surgery) as the two factors. Post hoc analysis was performed, when appropriate, by t-test
with Bonferroni’s adjustment. ap  .05 euglycemia vs. control.
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for these hemodynamic or biochemical
variables. All patients required exogenous
insulin during the control and the eugly-
cemic periods. Insulin administration
was significantly lower during the control
period than during euglycemia in both
groups of patients studied according to pro-
tocols 1 and 2. There were not significant
time effects or time  intervention inter-
action for insulin administration. Area
under the curve of glucose concentra-
tions was significantly lower during eug-
lycemia than during the control period in
both groups of patients studied according
to protocols 1 and 2. There were not
significant time effects or time  inter-
vention interaction for the area under the
curve of glucose concentrations. Plasma
glucose, insulin, and C-peptide concen-
trations, obtained at the end of the eugly-
cemic and control periods in subjects as-
signed to protocols 1 and 2, were
analyzed with repeated-measures analysis
of variance with intervention (euglyce-
mia/control) and time (day 1/day 2 after
surgery) as the two factors. There were
not significant time effects or significant
intervention time interaction. Values of
plasma glucose were near-normal during
the euglycemic period (5.8  0.4 mmol/L)
and were 70% 15% greater at the end of
the hyperglycemic control period. Plasma
insulin concentrations were not signifi-
cantly different at the end of the control
or euglycemic periods, possibly because a
greater insulin infusion during the inten-
sive treatment period was matched by a
greater endogenous insulin secretion
secondary to hyperglycemia during
conventional treatment. In fact, plasma
C-peptide concentrations tended (p 
.07) to be lower during euglycemia than
in the control period. The QUICKI index
of insulin sensitivity (25) was improved
(p  .02) during the euglycemic period
(0.29  0.01) in respect to the control
period (0.27  0.01). Table 3 shows net
balance of glucose across leg muscle cal-
culated during the last 20 mins of the
euglycemic and control periods. The rate
of glucose uptake across leg muscle
tended to be higher during euglycemia,
without achieving statistical significance.
Nonetheless, fractional glucose uptake
across leg muscle (i.e., the ratio between
the rates of glucose uptake and delivery
to leg muscle) was significantly higher
(p .05) during euglycemia (16% 4%)
than during the conventional treatment
(9%  3%).
Whole Body and Leg Muscle Protein
Kinetics. Plasma amino acid concentra-
tions and L[ring-2H5]phenylalanine trac-
er/tracee ratios in radial artery and fem-
oral vein obtained at the end of the
euglycemic and control periods in sub-
jects assigned to protocols 1 and 2 were
analyzed with repeated-measures analysis
of variance with intervention (euglyce-
mia/control) and time (day 1/day 2 after
surgery) as the two factors. There were
not significant time effects or significant
intervention time interaction. Figure 4
shows pooled results of phenylalanine
tracer/tracee ratios and concentrations in
radial artery and femoral vein obtained
during the last 20 mins of the euglycemic
and control periods in protocols 1 and 2.
Results show that the subjects were in
steady-state conditions at the end of the
euglycemic and control periods. Arterial
L[ring-2H5]phenylalanine tracer/tracee
ratio (mean SEM) was significantly (p
.01) higher during euglycemia (0.0188 
0.0013) than during the control period
(0.0165  0.0009). Consequently, whole
body phenylalanine rate of appearance
from whole body proteolysis was signifi-
cantly lower during euglycemia than dur-
ing the control period (mean change
from control period, 0.14  0.03
mol·kg1·min1) (Fig. 1). Femoral ve-
nous L[ring-2H5]phenylalanine tracer/
tracee ratios during the euglycemic and
control periods were 0.0152  0.0011
and 0.0141  0.0008, respectively. Arte-
rial phenylalanine concentrations were
not significantly different during the eu-
Table 2. Plasma hormone and selected substrate concentrations
Control Euglycemia Changes
Insulin (U/mL)
Artery 38 8 54  24 16 18
C-peptide (ng/mL)
Artery 2.3 0.7 0.9  0.3a 1.4  0.8
Glucose (mmol/L)
Artery 9.6 0.6 5.8  0.4b 3.8  0.6
Femoral vein 8.6 0.7 4.9  0.5b 3.7  0.6
Phenylalanine (mol/L)
Artery 107 5 104  3 3  4
Femoral vein 111 6 107  3 4  4
Leucine (mol/L)
Artery 112 8 129  8b 17  8
Femoral vein 113 8 128  9 15 10
Glutamine (mol/L)
Artery 348 21 381  27b 33  12
Femoral vein 380 23 447  41 67 31
Arginine (mol/L)
Artery 157 16 193  18b 36  13
Femoral vein 178 17 199  17b 21  8
ADMA (mol/L)
Artery 0.42 0.07 0.42  0.04 0.00 0.06
Femoral vein 0.51 0.04 0.54  0.04 0.03 0.06
SDMA (mol/L)
Artery 0.55 0.03 0.56  0.05 0.01 0.04
Femoral vein 0.70 0.04 0.68  0.05 0.02  0.07
Data are means  SEM of pooled values from protocols 1 and 2 obtained at the end of the control
and euglycemic periods. ap  .08; bp  .05, euglycemia vs. control (Wilcoxon matched-pairs signed-
ranks test). ADMA, asymmetrical dimethylarginines; SDMA, symmetrical dimethylarginines.
Table 3. Net balance of glucose and selected amino acids across leg muscle
Control Euglycemia Changes
Glucose (mol100 cc1min1) 1.34  0.60a 2.03  1.00a 0.69  0.50
Phenylalanine (nmol100 cc1min1) 11  3a 3  3b 8  2
Leucine (nmol100 cc1min1) 3  3 4  5 7 4
Glutamine (nmol100 cc1min1) 51  13a 97  22a,b 46  22
Arginine (nmol100 cc1min1) 30  11a 24  17 6  8
ADMA (nmol100 cc1min1) 0.21  0.14 0.30  0.12a 0.09  0.15
SDMA (nmol100 cc1min1) 0.22  0.06a 0.30  0.11a 0.08  0.10
Data are means  SEM of pooled values from protocols 1 and 2 obtained at the end of the control
and euglycemic periods. Negative numbers express net release. ap  .05 vs. zero, i.e., significant net
release or uptake (Wilcoxon matched-pairs signed-ranks test); bp  .05 euglycemia vs. control
(Wilcoxon matched-pairs signed-ranks test).
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glycemic and control periods (Table 2).
During the control period, net balance of
phenylalanine was significantly lower
than zero, indicating a negative balance
of muscle protein (Table 3). During eu-
glycemia, values of phenylalanine bal-
ance significantly changed from a value
that indicated net release to a value that
was not significantly different from
zero (3  3 nmol·100 mL1·min1).
Figure 2 shows the rates of leg muscle
protein synthesis and degradation dur-
ing the control and euglycemic periods.
Muscle protein synthesis was signifi-
cantly stimulated by euglycemia (mean
change from control period, 21  6
nmol phenylalanine·100 mL1·min1),
whereas rate of protein degradation was
not significantly different during the
two experimental periods (mean change
from control period, 13  7 nmol phe-
nylalanine·100 mL1·min1).
Leg Muscle Amino Acid Metabolism.
Euglycemia as compared with hypergly-
cemia was associated with higher arterial
leucine (18%  7%), glutamine (9% 
3%), and arginine (26%  14%) concen-
trations (Table 2). Glucose control did
not change ADMA or SDMA arterial con-
centrations. Glutamine net balance was
significantly lower than zero during both
the control and euglycemic periods, indi-
cating constant release of this amino acid
from skeletal muscle (Table 3). Net glu-
tamine release was significantly greater
during euglycemia than in the control
period (Table 3). Leucine net balance
across leg skeletal muscle was not differ-
ent from zero during the two experimen-
tal periods (Table 3). Figure 3 shows the
effect of glucose control on calculated
values of glutamine de novo synthesis
and of nonprotein leucine disposal across
leg muscle, an index of muscle leucine
oxidation. Euglycemia led to a signifi-
cantly greater glutamine de novo synthe-
sis rate in skeletal muscle (mean change
from control period, 54  23 nmol·100
mL1·min1). Muscle nonprotein leucine
disposal was significantly lower during
euglycemia (mean change from control
period, 19  6 nmol·100 mL1·min1).
Values of net balance of arginine, ADMA,
and SDMA are shown in Table 3. Glucose
control did not affect arginine, ADMA,
and SDMA release from skeletal muscle.
Nonetheless, arginine release from skele-
tal muscle was significantly lower than
zero only during the hyperglycemic con-
trol period. Rates of ADMA and SDMA
release from leg skeletal muscle were sig-
nificantly different from zero (except for
ADMA release during the control period).
Muscle proteolysis correlated with rates
of ADMA release in euglycemia (n  8,
r  .73, p  .03) and with rates of
SDMA release in the control period (n 
8, r  .70, p  .05); an inverse corre-
lation is due to the fact that muscle pro-
teolysis and net release of ADMA and
SDMA from leg muscle are, convention-
ally, positive and negative figures, respec-
tively).
DISCUSSION
Cancer and surgical stress interact to
aggravate insulin resistance, hyperglyce-
mia, muscle protein catabolism, and
amino acid depletion (4, 18 –20). We
compared the effects of insulin-mediated
tight glycemic control and of moderate
hyperglycemia, resulting from traditional
insulin treatment, on kinetics of protein
and selected amino acids in skeletal mus-
cle of female cancer patients receiving
total parenteral nutrition after major sur-
gery. Patients received 24 hrs of intensive
and conventional insulin treatment on
the first and second days after surgery in
randomized order. We found that eugly-
cemia as compared with hyperglycemia
was associated with: a) stimulated muscle
protein synthesis leading to neutral net
protein balance, b) lower muscle nonpro-
tein leucine disposal (an index of leucine
oxidation) leading to higher plasma
leucine concentrations, c) higher de novo
muscle glutamine synthesis leading to
higher plasma glutamine concentrations,
d) higher plasma arginine concentrations
by extramuscular mechanisms, e) no
changes of muscle release or plasma con-
centrations of the methylated arginines
ADMA and SDMA.
Plasma glucose concentrations were
near-normal during the euglycemic pe-
riod (i.e., about 6 mmol/L) and moder-
T
ra
ce
r-
tr
ac
ee
-r
at
io
0.012
0.017
0.022
0.012
0.017
0.022
µµ µµm
ol
/L
95
110
125
95
110
125
A B
C D
160’ 170’ 180’ 160’ 170’ 180’
CONTROL EUGLYCEMIA
Figure 1. L[ring-2H5]phenylalanine tracer/tracee ratios (A and B) and concentrations (C and D) in
radial artery (closed circles) and femoral vein (open circles) obtained at the end of the control (A and
C) and euglycemic (B and D) periods (mean  SEM of pooled values from protocols 1 and 2).
0.4
0.9
1.4
Control Euglycemia
→
←
W
ho
le
 b
od
y 
Ph
e
R
a 
fr
om
 p
ro
te
ol
ys
is
(( (( µµ µµ
m
ol
·k
g-
1
·m
in
-1
)
*
Figure 2. Effects of glucose control on whole body
phenylalanine (Phe) rate of appearance (Ra) from
proteolysis. Individual values of protocol 1 (open cir-
cles) and protocol 2 (filled circles). Arrows indicate
median values of pooled data. *p .05, euglycemia vs.
control (Wilcoxon’s matched-pairs signed-ranks test).
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ately elevated during the control period
(i.e., about 10 mmol/L). Plasma insulin
levels were not significantly different dur-
ing the two experimental periods. Thus, a
greater insulin infusion during the inten-
sive treatment period was possibly
matched by a greater endogenous insulin
secretion associated to greater plasma C-
peptide caused by hyperglycemia during
the conventional treatment period. Dif-
ferences in plasma glucose levels in the
two experimental conditions were much
greater than those in insulin concentra-
tions. This clearly indicates that 24 hrs of
tight plasma glucose control directly im-
proved insulin sensitivity in our patients.
When the quantitative insulin sensitivity
check index (25) was calculated from
plasma insulin and glucose values, we
found that insulin action was signifi-
cantly improved during euglycemia by
8%  3%. In addition, fractional muscle
glucose uptake (i.e., rate of leg glucose
uptake divided by rate of arterial leg glu-
cose delivery) was significantly greater
after intensive insulin treatment. These
data are in agreement with previous re-
sults in patients with diabetes mellitus
showing that insulin-mediated euglyce-
mia directly improves insulin sensitivity
and rapidly decreases insulin require-
ment to maintain euglycemia (27).
Patients were clinically stable during
the two study days. However, to prevent
potential effects of time-related changes
of muscle metabolism after surgery, the
euglycemic period either preceded (pro-
tocol 1) or followed (protocol 2) the hy-
perglycemic control period. For example,
whereas values of leg plasma flow tended
to be higher by 40%  24% during day 1
than during day 2 after surgery (Table 1),
their averages virtually did not change
during the euglycemic and control peri-
ods (mean change from control period,
0.2  0.4 mL·min1·100 mL1).
A major finding of this research was
that, after 24 hrs of insulin-mediated eu-
glycemia, the rate of glutamine release
from skeletal muscle was 100% greater
than during the conventional treatment
period. These changes were presumably
due to increased de novo net synthesis of
glutamine, assuming no changes in in-
tracellular-free glutamine pool. Plasma
glutamine levels changed in parallel to
muscle glutamine release, suggesting a
cause– effect relationship. In skeletal
muscle, glucose serves as the precursor
for the carbon skeleton of glutamine. Af-
ter glycolysis, pyruvate dehydrogenase is
the key enzyme responsible for the en-
trance of pyruvate in the tricarboxylic
acid cycle and for providing precursor for
glutamine synthesis. The importance of
this pathway in critically ill patients is
demonstrated by the fact that activation
of pyruvate dehydrogenase through di-
chloroacetate infusion increased intra-
muscular glutamine concentration, pre-
sumably by increasing synthesis of the
amino acid (28). Pyruvate dehydrogenase
is down-regulated in conditions of insulin
deficiency or resistance (29). Increased
muscle availability of glucose during
physiologic hyperinsulinemia accelerates
glucose conversion to glutamine (12, 13),
whereas such rise in carbon transfer from
glucose to glutamine was not observed in
insulin-deprived diabetic subjects (11).
Taken together, these results suggest
that an adequate insulin action is re-
quired to promote glutamine synthesis
during increased glucose availability,
whereas glutamine synthesis is down-
regulated during absolute or relative in-
sulin deficiency in hypercatabolic pa-
tients.
The present study demonstrates that
during parenteral feeding after major
surgery for cancer, hyperglycemia is as-
sociated with muscle protein catabolism,
despite an endogenous insulin response.
In contrast, euglycemia is associated with
neutral protein balance. Our data are in
excellent agreement with those of Gore et
al. (30), who showed that net muscle pro-
tein catabolism is proportional with lev-
els of plasma glucose in severely burned
patients. In addition, we suggest that the
mechanism of such anabolic effect of eu-
glycemia with improved insulin sensitiv-
ity is completely accounted for by protein
synthesis stimulation. Conversely, as ex-
pected (31), turnover rate of the essential
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amino acid phenylalanine, an index of
whole body proteolysis, decreased by 11%
in conditions of normal blood glucose as
compared with hyperglycemia. Thus, the
anticatabolic action of insulin-mediated
euglycemia involves stimulation of pro-
tein synthesis in skeletal muscle and in-
hibition of proteolysis in extramuscular
tissues, presumably within the splanch-
nic region.
Leucine and the other branched-chain
amino acids are largely oxidized in skel-
etal muscle. Their oxidation increases in
critically ill patients. Our results show
that during euglycemia, the rate of mus-
cle nonprotein leucine disposal (an index
of leucine oxidation) was 50% lower than
during the hyperglycemic control period.
This observation is consistent with other
reports (32) showing that increased
plasma glucose with relative insulin defi-
ciency in diabetes is associated with acti-
vation of the branched-chain alpha-
ketoacid dehydrogenase, which catalyzes
the first step in the leucine oxidation
pathway. A greater intracellular leucine
availability caused by inhibition of
leucine oxidation could have directly
stimulated protein synthesis (33) during
intensive insulin treatment and euglyce-
mia. In addition, an increased insulin
availability could have contributed to
stimulate muscle protein synthesis in eu-
glycemia (34).
Arginine depletion has been previ-
ously observed in patients with critical
illness (35) or cancer (36). In agreement
with data obtained in experimental diabe-
tes (37), our results suggest that insulin-
mediated euglycemia was associated with
greater plasma arginine concentration.
These changes were mediated by extra-
muscular mechanisms because rates of
leg arginine exchange were not affected
by glycemic control. In critically ill pa-
tients, high ADMA levels have been as-
sociated with increased mortality (10).
We have shown (in our knowledge, for
the first time) that ADMA and SDMA
can be significantly released from leg
muscle protein into the bloodstream,
thereby contributing to plasma levels of
these substrates when proteolysis is ac-
celerated.
CONCLUSIONS
This study shows that in catabolic pa-
tients, skeletal muscle acts as a central
effector during hyperglycemia, being at
the same time villain and victim to high
blood glucose and defective insulin ac-
tion. During hyperglycemia with relative
insulin deficiency, skeletal muscle greatly
decreases its uptake of glucose from sys-
temic circulation, thereby directly in-
creasing blood glucose levels. Conversely,
hyperglycemia with relative insulin defi-
ciency promotes muscle wasting and
blunted the ability of muscle to provide
glutamine to extramuscular tissues. This
latter effect could contribute to increased
morbidity and mortality in poorly con-
trolled critically ill patients and after sur-
gery. Tight glycemic control optimizes
skeletal muscle metabolism, leading to
greater systemic availability of glutamine
and leucine and to improved insulin sen-
sitivity.
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